Eurobio Scientific Société anonyme Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Eurobio Scientific Société anonyme ha un patrimonio netto totale di €178.8M e un debito totale di €88.2M, che porta il suo rapporto debito/patrimonio netto a 49.3%. Le sue attività totali e le sue passività totali sono rispettivamente €313.8M e €134.9M. L'EBIT di Eurobio Scientific Société anonyme è €12.9M rendendo il suo rapporto di copertura degli interessi 4.3. Ha liquidità e investimenti a breve termine pari a €86.6M.

Informazioni chiave

49.3%

Rapporto debito/patrimonio netto

€88.17m

Debito

Indice di copertura degli interessi	4.3x
Contanti	€86.59m
Patrimonio netto	€178.83m
Totale passività	€134.94m
Totale attività	€313.77m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Eurobio Scientific Société anonyme (EPA:ALERS) Held Back By Insufficient Growth Even After Shares Climb 32%

Jul 31

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Jul 29

Estimating The Fair Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Apr 07

Is Now The Time To Put Eurobio Scientific Société anonyme (EPA:ALERS) On Your Watchlist?

Mar 08

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Jan 03

Improved Earnings Required Before Eurobio Scientific Société anonyme (EPA:ALERS) Stock's 28% Jump Looks Justified

Dec 13

Should You Be Adding Eurobio Scientific Société anonyme (EPA:ALERS) To Your Watchlist Today?

Nov 20

Eurobio Scientific Société anonyme's (EPA:ALERS) Earnings Are Of Questionable Quality

May 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €146.7M ) di ALERS superano le sue passività a breve termine ( €54.5M ).

Passività a lungo termine: Le attività a breve termine di ALERS ( €146.7M ) superano le sue passività a lungo termine ( €80.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 0.9% ) di ALERS è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di ALERS si è ridotto da 53.2% a 49.3% negli ultimi 5 anni.

Copertura del debito: Il debito di ALERS è ben coperto dal flusso di cassa operativo ( 26.2% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di ALERS sono ben coperti dall'EBIT ( 4.3 x copertura).

Eurobio Scientific Société anonyme Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Diaxonhit ORD to Be Deleted from OTC Equity

Recent updates

Diaxonhit ORD to Be Deleted from OTC Equity

First half 2024 earnings released: EPS: €0.40 (vs €0.21 in 1H 2023)

Investor sentiment improves as stock rises 45%

NextStage AM, IK Partners, Denis Fortier, Cathie Marsais, Olivier Bosc, JeanMichel Carle-Grandmougin and Hervé Duchesne de Lamotte proposed to acquire remaining 65.96% stake in Eurobio Scientific Société anonyme (ENXTPA:ALERS) from Wietse Mulder and others for approximately €170 million.

Eurobio Scientific Société anonyme (EPA:ALERS) Held Back By Insufficient Growth Even After Shares Climb 32%

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released

Price target increased by 7.1% to €30.00

Eurobio Scientific Société anonyme, Annual General Meeting, Jun 13, 2024

Eurobio Scientific Société anonyme to Report Fiscal Year 2023 Results on Apr 10, 2024

Price target increased by 7.4% to €29.00

Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired Alpha Biotech Ltd.

Eurobio Scientific Appoints Catherine Courboillet to the Board of Directors

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 30%

First half 2023 earnings released

Now 20% undervalued after recent price drop

Price target increased by 7.7% to €28.00

Full year 2022 earnings released

Eurobio Scientific Société anonyme to Report First Half, 2023 Results on Oct 11, 2023

Less than half of directors are independent

First half 2022 earnings released

Eurobio Scientific Société anonyme, Annual General Meeting, Jun 12, 2023

Investor sentiment improved over the past week

Price target decreased to €32.00

Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired Genome Diagnostics B.V. from from Ampersand Capital Partners and others.

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Genome Diagnostics B.V. for ?135 million.

Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Genome Diagnostics B.V. for ?135 million.

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Price target decreased to €35.00

Eurobio Scientific Société anonyme to Report First Half, 2022 Results on Oct 11, 2022

Eurobio Scientific Launches 2 New Proprietary Tests for the Diagnosis of New Variants of Sars-Cov-2 and Monkeypox

Eurobio Scientific Société anonyme (ENXTPA : ALERS) acquired Biomedical Diagnostics Belgium.

No independent directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings released

Eurobio Scientific Société anonyme, Annual General Meeting, Jun 13, 2022

Estimating The Fair Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Is Now The Time To Put Eurobio Scientific Société anonyme (EPA:ALERS) On Your Watchlist?

Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)

Investor sentiment improved over the past week

Improved Earnings Required Before Eurobio Scientific Société anonyme (EPA:ALERS) Stock's 28% Jump Looks Justified

Eurobio Scientific Launches the First Pcr Test Allowing Simultaneous Sars-Cov-2 Virus Screening and Detection of the Delta and Omicron Variants in a Single Reaction

Should You Be Adding Eurobio Scientific Société anonyme (EPA:ALERS) To Your Watchlist Today?

First half 2021 earnings released

Investor sentiment improved over the past week

Eurobio Scientific launches its COVID antigen self-test

Eurobio Scientific Offers A New Proprietary Test for Simultaneous Detection of the SARS-COV-2 Virus and Characterization of Its New Mutations of Interest

Eurobio Scientific Société anonyme's (EPA:ALERS) Earnings Are Of Questionable Quality

Full year 2020 earnings released

Eurobio Scientific Announces Launch of New Proprietary Test, EurobioPlex SARS-CoV-2 Variants

Eurobio Scientific Société anonyme to Report Fiscal Year 2020 Results on Apr 14, 2021

Eurobio Scientific Expands Its Range of COVID-19 Tests with an Antigenic Rapid Test

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €18.35

Market bids up stock over the past week

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: €17.10

New 90-day high: €13.90

Eurobio Scientific SociÃ©tÃ© anonyme to Report First Half, 2020 Results on Oct 15, 2020

Eurobio Scientific Launches A First Rapid Diagnostic Test for the Detection of the SARS CoV-2 virus antigen

New 90-day high: €13.05

New 90-day high - €12.35

Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired TECOmedical AG.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane